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Summary
Prior studies identified a segment of the CD2 cytoplasmic domain between amino acid (aa) residues
253 and 287 as important in T lymphocyte signal transduction. This region contains two repeats
of the sequence motif PPPGHR, thought to form a "cage" structure involved in CD2-mediated
signaling. To evaluate this segment, a series of mutant human CD2 molecules were produced
by oligonucleotide-directed mutagenesis and inserted into the ovalbumin-specific, I-Ad-restricted
murine T-T hybridoma 3DO54.8 using the DOL retroviral system. CD2 M1 (271-272), CD2
M2 (278-279), and CD2 M4 (264-265) mutants replaced the positivelycharged adjacent as histidine
and arginine (HR) in the wild-type CD2 sequence with aspartic and glutamic acid (DE) at positions
271-272, 278-279, and 264-265, respectively. In addition, a truncation mutant, CD2 M3 (268),
containing only 57 ofthe 117 cytoplasmic as and terminating before the second PPPGHR sequence,
was generated. Stimulation oftransfectants CD2 FL, CD2 MI (271-272), and CD2 M2 (278-279)
with anti-T112 + anti-T113 antibodies resulted in a rise in cytosolic-free calcium ([Ca2+]i) and
subsequent interleukin 2 (IL2) secretion. In contrast, CD2 M4 (264-265) transfectants could
not be activated in either assay. Thus, alteration of histidine 264 and/or arginine 265 within
the first PPPGHR motif affects the process of signal transduction via CD2, whereas identical
mutations in residues at 271-272 or 278-279 were individually without effect. Consistent with
these data, CD2 M3 (268) transfectants were able to generate a detectable amount of IL2 via
CD2 triggering. These data support the notion that the PPPGHR motifat as 260-265 is important
for activation of T lymphocytes via the CD2 molecule.
T
he CD2 (T11) molecule is a 50-55-kD transmembrane
glycoprotein expressed on a vast majority of thymocytes
and virtually all peripheral T lymphocytes (reviewed in refer-
ence 1). Functional characterization of the human molecule
has clearly established that CD2 serves a dual role in medi-
ating T cell adhesion and activation (2-6). Based on micro-
chemical analysis of human CD2, as well as cDNA and/or
genomic cloning of mouse, rat, and human molecules, the
structure of the CD2 molecule has been well defined (reviewed
in reference 1). Human CD2 consists of a 185-amino acid
(aa) extracellular domain, a 25-aa transmembrane segment,
and a 117-aa cytoplasmic domain rich in prolines and basic
residues. By analysis ofmurine T cell transfectants expressing
the human wild-type CD2 cDNA as well as deletion mu-
tants, we and others have previously established that the CD2
cytoplasmic region is necessary for activation via CD2 (7-9).
More importantly, we were able to identify a segment of the
cytoplasmic domain between as 253 and 287 necessary for
CD2-mediated activation (7). This region contains four histi-
dines at as positions 264, 271, 278, and 282, and includes
two tandemly repeated segments (PPPGHR, as 260-265 and
274-279). A highly homologous region is found in murine
CD2 in a corresponding position as well. To further evaluate
the role of this segment for activation via CD2, a series of
substitution mutants of human CD2 have been generated by
oligonucleotide-directed mutagenesis and expressed in the
3DO54.8 murine T cell line for functional characterization.
Materials and Methods
Construction of Truncatedand Mutated Human CD2 Molecules and
Tmnsfection into a Murine T Cell Hybridoma. Constructs were gener-
ated by oligonucleotide-directed in vitro mutagenesis, as previously
described (7). The full-length human CD2 cDNA, PB2 insert (10),
was subdoned into the BamHI site of M13mp18. The synthetic
oligonucleotides used for mutation are 5'-CAGGCACCTAGTG-
ATGAGCCCCCGCCTCCT3' for CD2 M1 (271-272), which
changes the wild-type sequence CATCGT (His-Arg) into GATGAG
(Asp-Glu) at as 271-272; 5'-000TCCTGGAGATGAGGTTCA-
GCACCAG-3' for CD2 M2 (278-279), which changes the wild-
type sequence CACCGT (His-Arg) into GATGAG (Asp-Glu) at
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CD2M3 (268), which changes the wild-type sequenceGCA (Ala)
into TAA, a stop codon resulting in a CD2 molecule truncated
at as position 268 ; and 5'-CCACCACCTGGTGATGAGT000-
AGGCACCT3' forCD2 M4 (264-265), which changes the wild-
type sequenceCATCGT (His-Arg) intoGATGAG (Asp-Glu) at as
264-265 . The mutant DNAs were subcloned into the retroviral
expression vectorDOL and transfected by Cat + precipitation into
02 cell to generate the individual virus stock, as described in detail
previously (7) . Each virus was then used to infect the murine T
cell hybridoma 3DO54.8 . The G418-resistant clones were further
selected by indirect immunofluorescence for surface CD2 expres-
sion and maintained as described (7) . A single colony arising from
one well in selection media was considered clonal .
Sequence Analysis ofHuman CD2 cDNAs in the Mutant.
￿
DNA
fragments corresponding to by 739-1117 ofthe humanCD2 cDNA
(10) were generated by amplifying single-stranded cDNA gener-
ated with the 3' primer of CD2 and reverse transcriptase (Life
Sciences, St . Petersburg, FL) from the total cytosolic RNA ofeach
T cell clone byPCR with CD2-specific primers (11) . The condi-
tions used to performPCR were as follows : denaturation at 94°C
for 1 min, annealing at 55°C for 1 min, and extension at 72°C
for 1 min, for a total of 40 cycles of amplification . The 5' primer
5'-AGGATCCAACAGAGGAGTCGGAGAAAT3'corresponds to
by 739-758 ofCD2cDNA and contains a BamHI restriction en-
zyme recognition sequence . The 3' primer 5'-GGGATCCACA-
GTGCTTTTTATTGAA-3' corresponds to by 1100-1117 ofCD2
cDNA and includes aBamHI recognition sequence . The fragments
generated were subdoned into the BamHI site ofpGEM-4 blue
(Promega Biotec, Madison, WI) and subjected to double-stranded
DNA sequencing to confirm the presence of the correct mutation
for each clone .
Measurement ofCytosolic Ca' and 11,2 Production.
￿
Measure-
ment of cytosolic Cat* concentrations was determined according
to a previously described method (7) . For quantification of 11,2
production, 10 5 cells/well were incubated in 96-well round-
bottomed plates for 24 h in the presence ofeither OVA (1 mg/ml
final concentration) plus 105 A20-11 B lymphoma cells or anti-T112
+ anti-T113 (ascites 1:200) or culture medium . A 5-ng/ml final
concentration ofPMA was added to all experimental samples in-
cluding media control . Subsequently, supernatants were harvested
and titrated in triplicate for their ability to support the growth
of 10,000 CTL1r20 cells by [3H]thymidine incorporation, as pre-
viously described (7), in parallel to known concentrations of rIL2
(Biogen, Cambridge, MA) .
Results and Discussion
A series of mutants was generated within the cytoplasmic
region ofhuman CD2 including the two tandem repeats of
the sequencePPPGHR (Fig. 1) . In three mutants, two nega-
tively charged as residues (D and E) were substituted for ad-
jacent positively charged H andR residues in the CD2 se-
quence at as positions 264-265, 271-272, or 278-279 . In
another mutation, a termination codon was introduced at
as 268, thereby resulting in the loss of the secondPPPGHR
repeat as well as the other COOH-terminal components of
theCD2 cytoplasmic tail . These four modifiedcDNAs were
individually transfected into the 3DO54.8 cell line, a murine
T cell hybridoma specific for OVA in the context of the H-2
molecule (I-Ad), using a previously described retroviral
system (7) .
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Figure 1 .
￿
Schematic structure of transmembrane and cytoplasmic
regions of human CD2 and mutated CD2 molecules. The region
with the highest degree of homology (59%) between human and
mouse CD2 proteins is stippled, and the two repeated PPPGHR seg-
ments are marked in black . Restriction sites used to generate the
truncated CD2 molecules previously used in retroviral gene transfer
experiments (9) are indicated by arrows . Numbers in parentheses cor-
respond to as residues . The CD2 sequence between as 253 and 287,
previously shown to be essential for signal transduction, is given in
one-letter code. CD2 substitution and truncation mutants are di-
agrammed below the CD2 schematic with mutated as shown in cor-
responding positions in one-letter code . HR, histidine-arginine ; DE,
aspartic acid-glutamic acid; TM, transmembrane region .
Clones expressing each of these forms of CD2 were ob-
tained and compared with CD2FL clone 1, a clone derived
from 3DO54.8 transfected with wild-type human CD2 ex-
pressing a similar level of surface CD2 (7) . Nomenclature
of clones used in the subsequent functional analyses is as
follows : CD2M1 (271-272) clones expressCD2 cDNA with
aDE forHR substitution at as positions 271-272 ; CD2 M2
(278-279) clones express the DE forHR substitution at as
positions 278-279 ; CD2 M4 (264-265) clones express the
DE for HR substitution at as 264-265 ; and CD2 M3 (268)
clones express CD2 molecules truncated after 57 cytoplasmic
residues. The sequence of each mutation was confirmed by
both double-stranded sequencing ofthe plasmid used for trans-
fection as well as by sequencing the PCR products corre-
sponding to nucleotides 739-1117, as amplified from cellular
RNA derived from individual transfected clones.
Because perturbation of the CD2 extracellular segment with
antiT112 + antiT113 antibodies induces human T cell acti-
vation and initiates a rise in intracellular-free calcium
([Cal+]i) (1, 5), we tested the CD2 mutants for their ability
to alter [Ca2+], in the transfected 3DO54.8 cell lines in-
which they were expressed . In Fig. 2, a clear rise in [Ca 2 +],
(-200-nM increment) equivalent to the maximal level ob-
served after stimulation of the wild-type human CD2-
containing cells CD2 FL (clone 1) was reproducibly observed
after stimulation ofCD2 M1 (clone 232) andCD2M2 (clone
38.4) cells. In contrast, we repeatedly failed to observe any
calcium increase upon stimulation ofCD2 M3 (clone 176)
or CD2 M4 (clone 41) . Given that an immediate [Ca2+]i rise
was observed after addition ofthe calcium ionophore A23187
to each of these cells, the absence of a response was not due
to failure to load the cells with indo-1 . These results imply
that M3 and M4 mutations interfere with the function of
CD2 signal transduction that modulates [Ca2 +]i . TheseFigure 2 .
￿
Increase of jCa2' ] ; mediated upon CD2 triggering .
Changes in cytosolic Ca * concentration were monitored in cells
loaded with the calcium-sensitive dye indo-1 . Cells were stimulated
with either anti-T112 (Iold24C1) plus anti-T113 (Imono2A6) mAbs
(ascites 1:200 dilution) (filled arrowhead) or calcium ionophore A23187
(open arrowhead) . Results are expressed as ratio of 410:480-nm indo-1
fluorescence in arbitrary units (y-axis) vs. time in minutes (x-axis) .
One arbitrary unit represents -200 nM [Ca'*] ; . The surface expres-
sion of the CD2 molecule in these clones is -3,000-8,000 mole-
cules/cell. Results are representative of five experiments .
findings were confirmed with two additionalM3 clones (clones
17 and 95) and two additionalM4 clones (clones 36 and 122) .
Perturbation of the CD2 molecule with a combination of
anti-T112 + anti-T113 mAbs was previously shown to result
in 11,2 production (2) . We, therefore, next determined whether
this mitogenic combination of anti-CD2 mAbs stimulated
any of the CD2 mutants, and compared the level of IL2 pro-
duced with that obtained by stimulating each cell type with
OVA in the context of I-Ad APC. As shown in Fig. 3, sub-
stantial levels of 11,2 were produced by CD2 FL (clone 1),
CD2 M2 (clone 38.1), CD2 M3 (clone 176), and CD2 M4
(clone 41) upon antigenic stimulation, as assayedby the ability
of supernatants from transfected cells to induce proliferation
ofCTLL20 . The amount of 11,2 generated from the CD2
FL clone after CD2 triggering was comparable with that after
antigen stimulation . A similar result was obtained for CD2
M2 cells (Fig. 3) . As we previously reported, this was also
the case forCD2M1 (clone 232; reference 7) . Although cells
of the CD2 M2 clone 38.1 express higher levels of surface
CD2 than CD2 FL, no defect in CD2 M2 function was ob-
served upon triggering cells ofthe CD2M2 clone 38.4, which
express levels ofCD2 comparable with that on CD2 FL cells
(see Fig . 3 legend) . Thus, the 11,2 induction function of the
CD2M2 molecule is not altered. In contrast, anti-CD2 stimu-
lated no detectable IL2 production from CD2 M4 and in-
duced significantly less 11,2 from CD2 M3 relative to stimu-
lation by antigen andMHC . These results indicate that IL2
production from TCR stimulation of CD2 M4 and CD2
M3 clones is intact but that mutations ofthe CD2 molecule
expressed in these clones has altered their signaling capacity.
As indicated in the Fig. 3 legend, each of three CD2 M4
clones (M4 clone 36, M4 clone 41, and M4 clone 122) failed
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￿
Stimulation of IL2 production through wild-typf and
mutant CD2 molecules expressed on murine T cells . Serial twofold
dilutions of culture supernatants from unactivated and stimulated
transfectants have been analyzed for their capacity to support the
growth of the CTLI.20 11r2-dependent cell line, as evaluated by
1 3H]thymidine incorporation . Each point is the mean of a triplicate
determination (with SD <5%, in general). The proliferative effect of
known amounts of rIL2 (Biogen) is shown in the right panel of the
figure. Specific clones used in this experiment were CD2 FL clone 1,
CD2 M2 clone 38 .1, CD2 M3 clone 176, and CD2 M4 clone 41 .
The CD2 expression of these clones present in copy number per cell
is 5,000, 30,000, 8,000, and 4,000, respectively. This experiment is
representative of five independent experiments using in addition
clones CD2 FL clone 2, CD2 M2 clone 38.4, CD2 M3 clone 95,
CD2 M4 clone 36, and CD2 M4 clone 122, with 4,500, 3,500,
4,000, 2,500, and 3,500 CD2 molecules expressed per cell, respec-
tively, as evaluated by indirect immunofluorescence and FRCS analysis.
to produce IL2 upon CD2 stimulation . Furthermore, the
lack of IL2 production was not a consequence of reduced
CD2 expression, because the level ofCD2 surface expression
on the nonfunctional M4 series can be compared with the
level ofCD2 found on the functional M2 series (3,000-4,000
copies/cell, respectively) .
Collectively, the above results show that alteration of the
positively charged histidine 264 and arginine 265 residues
within the first PPPGHR motif of the human CD2 cyto-
plasmic domain markedly affects the process of signal trans-
duction via this molecule. In contrast, alteration of histidine
and arginine residues at positions 271-272 or 278-279 were
without detectable effect, implying that the effect ofthe non-
conservative substitutions is strictly sequence position depen-
dent . Such a finding might not have been anticipated if the
histidine residues were each involved in forming a portion
of a cage for an ion or small, charged regulatory molecule.
While the position of residue substitutions in the mutant
CD2 moleculesmay define the precise site(s) involved inCD2
signal transduction, we cannot exclude the possibility that
the nonconservative substitutions structurally altered theCD2
cytoplasmic domain elsewhere . Furthermore, the ability of
the M3 truncation to function in signaling 11,2 production,
C02 FL . C02 M2 C02 M3 C02 M4 rIL2
Ovelbumin
1
1
l
1
1
1
1
Anti 1112
Tits l \
Medium balthough at reduced levels relative to CD2 FL, supports the
importance of the histidine and/or arginine residues in the
first PPPGHR motif. These data are also consistent with our
earlier observations from analysis of a panel of CD2 cyto-
plasmic truncation mutants (7), and extend the findings by
suggesting that some component between as 268-287, aside
from the histidine residues, contributes to signal transduction.
A number ofimportant issues are raised by the data herein.
First, what is the structural nature o£ the PPPGHR motif?
We suspect that a core sequence consisting of PPGH may
be the critical structural element, in view of the fact that
the PPGH repeat, but not the entire PPPGHR motif, is present
in a corresponding position of the murine CD2 sequence (1).
Second, it is yet to be proven whether this CD2 segment
is required for function or, rather, facilitates function. For
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